Could Viking Therapeutics Become the Next Novo Nordisk?
The much-feted biotech Viking Therapeutics (NASDAQ: VKTX) is aiming for Novo Nordisk's (NYSE: NVO) cash cow, the market for weight loss drugs. If its ambitions are fulfilled, it has a shot at becoming as large as its big pharma rival.
To see why this possibility is more than a pipe dream, let's start by making some quick calculations. That will help us to understand Viking's chances of becoming the next Novo Nordisk, based on how much it needs to grow from where it is now.
There are a couple of factors that are working in Viking's favor. As a pre-revenue biotech stock, its value is largely determined by the quality of its clinical trial data, the cash it has on hand, and the hype pertaining to its development programs (assuming there is any).
Source Fool.com
